Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240,968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort.
Zou Z, Gu Y, Liang L, Hao X, Fan C, Xin T, Zhao S, Liu Z, Guo Y, Ma K, Li H, Zhang C, Shan L, Zhang Y, Dong G, Peng Y, Shen F, Song X, Christopoulos P, van der Wekken AJ, Okuda K, Ekman S, Xing P, Li J. Zou Z, et al. Among authors: zhang c, zhang y. Transl Lung Cancer Res. 2022 Dec;11(12):2495-2506. doi: 10.21037/tlcr-22-803. Transl Lung Cancer Res. 2022. PMID: 36636411 Free PMC article.
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.
Zhang L, Wang L, Wang J, Chen J, Meng Z, Liu Z, Jiang X, Wang X, Huang C, Chen P, Liang Y, Jiang R, Wang J, Zhong D, Shang Y, Zhang Y, Zhang C, Huang D. Zhang L, et al. Among authors: zhang c, zhang y. Mol Cancer. 2023 Aug 5;22(1):124. doi: 10.1186/s12943-023-01823-w. Mol Cancer. 2023. PMID: 37543587 Free PMC article. Clinical Trial.
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy.
Zhong H, Zhang X, Tian P, Chu T, Guo Q, Yu X, Yu Z, Li Y, Chen L, Liu J, Zhang Y, Guan Y, Shi X, Wang J, Zhao Y, Han B. Zhong H, et al. Among authors: zhang x, zhang y. J Immunother Cancer. 2023 Aug;11(8):e006887. doi: 10.1136/jitc-2023-006887. J Immunother Cancer. 2023. PMID: 37597849 Free PMC article. Clinical Trial.
Immunotherapy with radiotherapy fails to improve prognosis of patients with stage IV non-small cell lung cancer: a retrospective cohort analysis of the THUNDER-2 study.
Liu L, Yuan M, Ding Z, Feng H, Zhang X, Liang N, Wang W, Wang J, Zhang Y, Zhou S, Kim AW, Castiglioni S, Suwinski R, Wang H, Hu P, Zhang J. Liu L, et al. Among authors: zhang j, zhang x, zhang y. Transl Lung Cancer Res. 2022 Dec;11(12):2507-2520. doi: 10.21037/tlcr-22-843. Transl Lung Cancer Res. 2022. PMID: 36636420 Free PMC article.
Targeting complement C5a to improve radiotherapy sensitivity in non-small cell lung cancer.
Yuan M, Wang C, Wu Y, Qiao L, Deng G, Liang N, Chen F, Liu L, Chen Y, Yang Y, Wang H, Liu T, Yang X, Zhang Y, Lv Y, Suwinski R, Hu P, Zhang Y, Zhang J. Yuan M, et al. Among authors: zhang j, zhang y. Transl Lung Cancer Res. 2023 May 31;12(5):1093-1107. doi: 10.21037/tlcr-23-258. Epub 2023 May 29. Transl Lung Cancer Res. 2023. PMID: 37323177 Free PMC article.
240,968 results
You have reached the last available page of results. Please see the User Guide for more information.